Research Analysts’ Weekly Ratings Updates for Alkermes (ALKS)

Several brokerages have updated their recommendations and price targets on shares of Alkermes (NASDAQ: ALKS) in the last few weeks:

• 5/13/2025 – Alkermes was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.
• 5/5/2025 – Alkermes was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 5/2/2025 – Alkermes had its “neutral” rating reaffirmed by analysts at HC Wainwright.
• 5/2/2025 – Alkermes had its price target raised by analysts at Royal Bank of Canada from $39.00 to $40.00. They now have a “sector perform” rating on the stock.
• 5/2/2025 – Alkermes had its price target raised by analysts at Robert W. Baird from $38.00 to $41.00. They now have an “outperform” rating on the stock.
• 4/28/2025 – Alkermes had its “underperform” rating reaffirmed by analysts at Royal Bank of Canada.
• 4/28/2025 – Alkermes had its “sector perform” rating reaffirmed by analysts at UBS Group AG.
• 4/28/2025 – Alkermes had its price target lowered by analysts at UBS Group AG from $38.00 to $33.00. They now have a “neutral” rating on the stock.
• 3/27/2025 – Alkermes had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $40.00 to $52.00. They now have a “buy” rating on the stock.

Alkermes Trading Up 1.9%

ALKS stock opened at $31.21 on Friday. The stock has a market capitalization of $5.15 billion, a PE ratio of 14.38, a price-to-earnings-growth ratio of 2.20 and a beta of 0.51. Alkermes plc has a 12-month low of $22.90 and a 12-month high of $36.45. The stock’s 50 day simple moving average is $30.62 and its 200 day simple moving average is $30.64.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Thursday, May 1st. The company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.19). Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The business had revenue of $306.51 million for the quarter, compared to the consensus estimate of $307.53 million. During the same period in the previous year, the company earned $0.43 earnings per share. The company’s revenue for the quarter was down 12.6% compared to the same quarter last year. On average, research analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.

Institutional Trading of Alkermes

A number of institutional investors have recently made changes to their positions in ALKS. Barclays PLC lifted its position in Alkermes by 108.8% during the third quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after purchasing an additional 220,893 shares during the period. Franklin Resources Inc. raised its position in Alkermes by 2.5% in the third quarter. Franklin Resources Inc. now owns 120,006 shares of the company’s stock worth $3,486,000 after acquiring an additional 2,903 shares during the period. Wedge Capital Management L L P NC lifted its position in Alkermes by 1.3% during the fourth quarter. Wedge Capital Management L L P NC now owns 111,909 shares of the company’s stock valued at $3,219,000 after purchasing an additional 1,455 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Alkermes by 2.6% during the 4th quarter. Nisa Investment Advisors LLC now owns 93,532 shares of the company’s stock valued at $2,690,000 after acquiring an additional 2,373 shares during the period. Finally, Exchange Traded Concepts LLC increased its holdings in Alkermes by 3.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 30,950 shares of the company’s stock worth $890,000 after acquiring an additional 897 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.